Novo Nordisk

This hot weight-loss drug stock may have a surprise challenger Barchart05:47
ECO 2026: Redefine-1 demonstrates CagriSema’s improvement in body composition Pharmaceutical Technology23:57
Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial PharmaTimes20:23
Can Novo Nordisk close the gap to Eli Lilly? Investors Chronicle16:53
Cellular Intelligence scoops up Novo's Parkinson's therapy pharmaphorum18:39
Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses … Novo Nordisk16:14
Best healthcare stocks to buy in 2026 The Motley Fool05:00

Latest News

In the last 6 hours

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party The Motley Fool10:56

Supreme Court Rejects Drugmakers’ Challenge to Medicare Price Negotiation Program Barchart10:46

In the last 8 hours

Eli Lilly Stock: Next Stop $2,000? The Motley Fool08:54

Earlier today

Drug companies spurned by Supreme Court on price negotiation law Boston Globe07:16

Ozempic Costs Set to Be Capped in Maryland After Drug Board Vote Bloomberg Law06:41

Yesterday

Patients For Affordable Drugs, Public Citizen, Legal Expert & Patient React to SCOTUS Denying Pharma Lawsuits… Public Citizen23:50 18-May-26

Novo Nordisk's Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi… Proactive Investors (UK)22:18 18-May-26

Indian company launches generic Ozempic in Canada, new competitor to Novo Nordisk Sweden Herald21:55 18-May-26

In the last 7 days

Could Eli Lilly's Next Weight Loss Drug Waylay Wegovy -- and Even Zap Zepbound? The Motley Fool15:21 17-May-26

Is Kailera Therapeutics a Buy After Its Sizzling IPO? The Motley Fool00:47 17-May-26

HIMS Stock Dips 14.3% Since Q1 Earnings: Should You Still Hold or Sell? Zacks01:21 16-May-26

Buy, Sell, or Hold Novo Nordisk at $46? The Motley Fool01:13 16-May-26

This Hot Weight-Loss Drug Stock May Have a Surprise Challenger Barchart05:47 15-May-26

Best Healthcare Stocks to Buy in 2026 The Motley Fool05:00 15-May-26

Novo Nordisk worked in partnership with NIHR Industry Hub to harness the power of primary care to rapidly activate 2… National Institute for Health Research02:19 15-May-26

Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure? Zacks01:22 15-May-26

Higher dose Wegovy demonstrates nearly 28% weight loss in early responders according to new analyses presented at the… Riyadh Daily23:39 14-May-26

Veeva Commercial Summit to Feature Biopharma's AI Successes and the Path to Agentic Commercial PR Newswire (Press Release)21:03 14-May-26

Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? The Motley Fool19:11 14-May-26

Novo Nordisk’s high-dose Wegovy touts near 28% weight loss in early responders Clinical Trials Arena18:57 14-May-26

ICRISAT and CIMMYT Launch New Initiative to Fast-Track Climate-Resilient Crops for Dryland Farmers in Africa and India CGIAR17:59 14-May-26

Can Uber Make an “Everything” App? The Motley Fool07:30 14-May-26

Is Novo Nordisk's Rebound for Real--or Just a Head Fake? The Motley Fool03:26 14-May-26

Canadians can now get Ozempic, Wegovy delivered to their homes. Here’s how Global News03:00 14-May-26

Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead Zacks02:56 14-May-26

ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition Pharmaceutical Technology23:57 13-May-26

New fat loss pill 'saw 1 in 4 users lose over 10pc body weight in four months' Daily Record21:49 13-May-26

Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial PharmaTimes20:23 13-May-26

Delhi High Court denies interim relief in semaglutide patent dispute amid imminent expiry IAM19:54 13-May-26

Novo, Lilly trade oral GLP-1 data readouts at ECO pharmaphorum19:44 13-May-26

Can Novo Nordisk close the gap to Eli Lilly? Investors Chronicle16:53 13-May-26

Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo… Novo Nordisk16:18 13-May-26

New pill sees people lose fifth of body weight in major study The Mirror16:12 13-May-26

New fat-loss pill saw people lose more than a fifth of body weight Somerset Live16:08 13-May-26

The $59B Quiet Shift Reshaping How Patients Access Care PR Newswire (Press Release)00:32 13-May-26

Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock Zacks00:05 13-May-26

New weight loss pills could become long term obesity treatments The National23:43 12-May-26

AI to accelerate Novo Nordisk's Parkinson’s cell therapy European Pharmaceutical Review21:47 12-May-26

Novo says high-dose Wegovy can cause 28% weight loss pharmaphorum21:11 12-May-26

Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and… Novo Nordisk20:38 12-May-26

Cellular Intelligence scoops up Novo's Parkinson's therapy pharmaphorum18:39 12-May-26

Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses … Novo Nordisk16:14 12-May-26

The AI energy crisis is bad. Wait until quantum arrives Sifted14:09 12-May-26

FDA Grants Fast Track Designation to Coramitug for ATTR-CM Rare Disease Advisor08:50 12-May-26

Novo Nordisk Hands Parkinson’s Cell Therapy To Cellular Intelligence Scrip Pharma Intelligence07:33 12-May-26

Novo Nordisk hands over Parkinson’s therapy to Boston-based AI startup Boston Globe05:32 12-May-26

AI in Health Care Is Scaling Quickly—As Regulation Lags, Internal Controls Need to Keep Pace JD Supra03:56 12-May-26

Cellular Intelligence licenses Novo’s shelved Parkinson’s cell therapy programme Pharmaceutical Technology03:34 12-May-26

Novo Nordisk hands shelved Parkinson’s cell therapy to Zuckerberg-backed Cellular Intelligence The Next Web03:16 12-May-26

Funding Radar: The Novo Nordisk Foundation’s 2027 challenge Science|Business02:59 12-May-26

NVO Rallies 21% in a Month: How Should Investors Play the Stock? Zacks02:29 12-May-26

In the last month

Novo Nordisk GLP-1 pill launch impresses but price erosion keeps Citi on the sidelines Proactive Investors (UK)23:19 11-May-26

Mark Zuckerberg backed-Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy The Economic Times23:17 11-May-26

Cellular Intelligence strikes deal with Novo Nordisk to advance Parkinson’s cell therapy Jerusalem Post22:55 11-May-26

Novo Nordisk microRNA drug fluffs its lines in heart failure pharmaphorum22:47 11-May-26

Cellular Intelligence, an AI-native TechBio, Enters Agreement with Novo Nordisk to Advance… PR Newswire (Press Release)22:32 11-May-26

Strong boost for Novo Nordisk shares as Wegovy pill sales in US lift stock Sweden Herald21:11 11-May-26

Tour of Türkiye cyclists champion diabetes awareness for youth Yeni Şafak20:03 11-May-26

LanzaTech & DTU to Open Biofoundry to Turn Carbon Emissions Into High-Value Products Green Queen19:11 11-May-26

Semaglutide shows sustained weight loss benefits in older adults News-Medical.Net14:34 11-May-26

Amazon stocking Ozempic pills at kiosks, offering same-day delivery FOX13 Seattle04:38 11-May-26

Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders? The Motley Fool20:18 9-May-26

How Ozempic and GLP-1 weight-loss drugs are driving a whey protein boom for Irish dairy Irish Examiner15:08 9-May-26

Can Platform Expansion Support Hims & Hers Stock Before Q1 Earnings? Zacks04:07 9-May-26

Wegovy pill on track for blockbuster status as Novo Nordisk navigates crowded GLP-1 market Proactive Investors (UK)00:07 9-May-26

Novo’s CEO champions “record-breaking start” for Wegovy pill in US market Pharmaceutical Technology20:56 8-May-26

New investment to democratise access to genomics technology University of Copenhagen10:24 8-May-26

Forget Eli Lilly: These 2 Stocks Have More Upside The Motley Fool04:26 8-May-26

Novo Nordisk is big-game hunting Semafor03:39 8-May-26

Amazon to carry Ozempic at US kiosks for diabetes patients, offer same-day delivery The Telegraph, Calcutta21:57 7-May-26

Wegovy® access expanded for Medicare beneficiaries living with obesity through the Medicare… PR Newswire (Press Release)21:05 7-May-26

Novo Nordisk Foundation, Grundfos Foundation and WFP Announce Record Private-Sector Commitment to Transform School… World Food Programme (Press Release)21:04 7-May-26

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights Business Wire (Press Release)21:02 7-May-26

Sales of Novo Nordisk's New Weight-Loss Pill Are Off To a Strong Start. The Stock Is Rising Investopedia21:01 7-May-26

Lilly’s Mounjaro overtakes Keytruda as world’s top-selling drug Boston Globe09:09 7-May-26

Novo Nordisk shares rise on strong demand for GLP-1 pill Semafor08:39 7-May-26

NVO Q1 Earnings & Sales Top Estimates, 2026 Outlook Raised, Stock Up Zacks02:59 7-May-26

Novo Nordisk beats estimates, raises guidance on Wegovy pill surge Proactive Investors (US)01:01 7-May-26

Novo Nordisk, Eli Lilly fined by French regulator over obesity drug promotions FiercePharma00:09 7-May-26

Ozempic (Semaglutide) Tablets Available Nationwide Starting May 4 Renal and Urology News00:08 7-May-26

STAT Plus: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price STAT23:41 6-May-26

US launch of weight loss pills boosts Wegovy maker Novo Nordisk The Irish Times22:14 6-May-26

Novo Nordisk raises 2026 guidance after Wegovy pill drives stronger-than-expected Q1 earnings Manufacturing Chemist22:08 6-May-26

Wegovy Pill Debut 'Fattens' Novo Nordisk's Profit Outlook Benzinga21:48 6-May-26

Novo Nordisk shares soar as sales of Wegovy weight loss pill fly The Independent21:43 6-May-26

Shares in Novo Nordisk jump after Wegovy pill sales smash forecasts ShareCast21:07 6-May-26

Wegovy maker Novo Nordisk boosted by successful weight loss pill launch Evening Standard20:44 6-May-26

Novo Nordisk buoyed by outperforming oral Wegovy in Q1 pharmaphorum19:20 6-May-26

Novo Nordisk gains 7% on Q1 beat: is it too late to buy NVO stock? Invezz18:42 6-May-26

Korea begins insurance coverage for Novo Nordisk’s weekly growth hormone drug Korea Biomedical Review18:19 6-May-26

Novo Nordisk raises outlook as Q1 profit beats forecast RTE16:49 6-May-26

Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026 Novo Nordisk15:48 6-May-26

Novo Nordisk is doing better than expected as pill version lifts Wegovy sales Sweden Herald15:46 6-May-26

FDA Pressure Tests Hims And Hers Weight Loss Growth Story Simply Wall St08:05 6-May-26

Emcure hits the “sweet spot” on weightloss brand Poviztra, says executive The Hindu Business Line01:42 6-May-26

Aspen to release first commercial batches of locally-made human insulin Engineering News01:10 6-May-26

Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the… PR Newswire (Press Release)23:09 5-May-26

Billion-dollar decline expected in Novo Nordisk profits Sweden Herald18:04 5-May-26

Novo Nordisk's weight-loss pill boom faces price war test The Hindu Business Line17:28 5-May-26

STAT Plus: French regulator fines Novo and Lilly over weight loss ad campaigns STAT15:18 5-May-26

Here's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 Months The Motley Fool06:21 5-May-26

Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock? Zacks03:14 5-May-26

Comments on the Maryland PDAB Draft Proposed Regulations on an Upper Payment Limit for Ozempic Public Citizen02:31 5-May-26

Parker Waichman LLP Files Lawsuit on behalf of South Carolina Resident Alleging Development of… PR Newswire (Press Release)22:43 4-May-26

Novo Nordisk to launch Ozempic for type 2 diabetes in US Pharmaceutical Technology19:04 4-May-26

Falling kilos from diet pills lift the hair industry Sweden Herald16:48 4-May-26

Health Canada approves two generic versions of Ozempic Sooke News Mirror03:00 3-May-26

Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026) The Motley Fool22:12 2-May-26

FDA Proposal Could Support Novo Nordisk GLP‑1 Exclusivity And Valuation Simply Wall St16:01 2-May-26

Ozempic-maker sees Singapore as a platform to pilot treatments for diabetes, obesity The Straits Times07:02 2-May-26

Novo rebrands diabetes pill as Ozempic to tap blockbuster name The Economic Times05:51 2-May-26

GLP-1 Lawsuits: An Update and What You Should Know as a Prescriber Endocrinology Advisor00:11 2-May-26

US Proposes Restricting Weight-Loss Drug Copies Channels Television23:04 1-May-26

GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients Business Wire (Press Release)22:15 1-May-26

Novo Nordisk's Ozempic® pill, the only FDA-approved oral peptide GLP-1 medication for adults… PR Newswire (Press Release)22:09 1-May-26

view more headlines

19 May 10:56

About our Novo Nordisk news

Latest news on Novo Nordisk, a global healthcare company focused on diabetes care, obesity treatment, and other serious chronic diseases. Get updates on Novo Nordisk's products, research, financial performance, and stock price.

Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark. Founded in 1923, the company has grown to become a global leader in diabetes care, with a strong presence in the fields of hemophilia, growth hormone therapy, and obesity treatment. Novo Nordisk's key products include insulin analogs like Tresiba and Levemir, GLP-1 receptor agonists such as Victoza and Ozempic, and obesity drugs like Saxenda and Wegovy.

Stay informed about the latest developments in Novo Nordisk's research and development pipeline, including updates on clinical trials, regulatory approvals, and new product launches. Our feed covers the company's ongoing efforts to innovate and improve treatments for diabetes, obesity, and other metabolic disorders, such as the development of oral semaglutide and the exploration of novel drug targets.

In addition to product news, our Novo Nordisk feed keeps you updated on the company's financial performance, including quarterly earnings reports, sales figures, and market share data. We also cover key events and announcements that may impact Novo Nordisk's stock price (NYSE: NVO), such as strategic partnerships, acquisitions, and leadership changes.

Beyond the business aspects, our feed highlights Novo Nordisk's commitment to corporate social responsibility and sustainability. From initiatives to improve access to diabetes care in developing countries to efforts to reduce the company's environmental footprint, we provide a comprehensive view of Novo Nordisk's impact on global health and society.

As the prevalence of diabetes and obesity continues to rise worldwide, Novo Nordisk plays a crucial role in addressing these global health challenges. Our NewsNow feed on Novo Nordisk brings you the most relevant and up-to-date information from reliable sources, helping you stay informed about this innovative and influential healthcare company.

Novo Nordisk

Latest News

About our Novo Nordisk news

Pharmaceuticals Top Stories

Business Top Stories